Comment
Author: Admin | 2025-04-28
February 2013.^ "Drittewelle 2C-B Packaging". Erowid.org. 2002. Retrieved 25 September 2013.^ Pachico E (1 November 2012). "2CB Now Drug of Choice for Colombia Elite". InSight Crime. Retrieved 11 February 2013.^ Gahlinger P (2004). Illegal Drugs: A Complete Guide to Their History, Chemistry, Use and Abuse. Penguin. pp. 343–344. ISBN 9780452285057.^ "2CB chosen over traditional entheogen's by South African healers". Tacethno.com. 2008-03-27. Retrieved May 15, 2012.^ The Nexus Factor - An Introduction to 2C-B Erowid^ Ubulawu Nomathotholo Pack Photo by Erowid. © 2002 Erowid.org^ a b "Erowid 2C-B Vault: Basics". Erowid. 2011-02-20. Retrieved 2013-09-25.^ Palamar JJ, Acosta P (January 2020). "A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines". Human Psychopharmacology. 35 (1): e2719. doi:10.1002/hup.2719. PMC 6995261. PMID 31909513.^ a b Caudevilla-Gálligo F, Riba J, Ventura M, González D, Farré M, Barbanoj MJ, et al. (July 2012). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects". Journal of Psychopharmacology. 26 (7): 1026–35. doi:10.1177/0269881111431752. PMID 22234927. S2CID 35535891.^ Bronson ME, Jiang W, DeRuiter J, Clark CR (1995). "A behavioral comparison of Nexus, cathinone, BDB, and MDA". Pharmacology, Biochemistry, and Behavior. 51 (2–3): 473–475. doi:10.1016/0091-3057(95)00013-M. PMID 7667371. S2CID 32246652.^ a b "Erowid 2C-B Vault: Effects". Erowid. Retrieved 2013-09-25.^ a b "Drugscope: 2C-B". Drugscope. Jan 2004. Archived from the original on 2013-09-28. Retrieved 2013-09-25.^ "2C-B - Dancesafe.org". Dancesafe. Retrieved 2013-09-25.^ "Shulgin, A (1991) PIHKAL". Erowid.org. Retrieved May 15, 2012.^ a b Mallaroni P, Mason NL, Reckweg JT, Paci R, Ritscher S, Toennes SW, et al. (August 2023). "Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition". Clin Pharmacol Ther. 114 (2): 423–433. doi:10.1002/cpt.2958. PMID 37253161.^ a b c Carmo H, Hengstler JG, de Boer D, Ringel M, Remião F, Carvalho F, et al. (January 2005). "Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human". Toxicology. 206 (1): 75–89. Bibcode:2005Toxgy.206...75C. doi:10.1016/j.tox.2004.07.004. PMID 15590110.^ "Erowid 2C-B Vault : FAQ v1.0". erowid.org.^ "Erowid 2C-B Vault : Dose/Dosage".^ Ambrose JB, Bennett HD, Lee HS, Josephson SA (May 2010). "Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion". The Neurologist. 16 (3): 199–202. doi:10.1097/NRL.0b013e3181a3cb53. PMID 20445431. S2CID 35035721.^ a b de Boer D, Gijzels MJ, Bosman IJ, Maes RA (1999). "More data about the new psychoactive drug 2C-B". Journal of Analytical Toxicology. 23 (3): 227–8. doi:10.1093/jat/23.3.227. PMID 10369336.^ Cole MD, Lea C, Oxley N (October 2002). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review
Add Comment